Arrow International’s Carl Anderson
This article was originally published in The Gray Sheet
Executive Summary
Newly appointed chairman and CEO will succeed Marlin Miller Sept. 1. Anderson currently is vice chairman of Arrow and general manager of the firm's critical care business. The exec has been a director since 1998 and has served with ABC School Supply, Inc., James River Corp. and Procter & Gamble. Miller, who has been with Arrow since 1975, will continue as a director and chairman emeritus. Arrow expects a CE mark for its LionHeart left-ventricular assist device within weeks...
You may also be interested in...
American Heart Association 2003 Scientific Sessions In Brief
Arrow takes aim at Thoratec data: Adverse event rate associated with Arrow International's LionHeart left-ventricular assist device in the European Clinical Utility Baseline Study (CUBS) is comparable to Thoratec's HeartMate VE in the REMATCH trial, Arrow contends. Results of the destination LVAD therapy trial were presented by John Boehmer, MD, Pennsylvania State University, at the American Heart Association annual scientific sessions in Orlando Nov. 10. In CUBS, LionHeart was associated with 7.56 adverse events per patient-year, compared with 6.39 in REMATCH. Boehmer notes, however, that CUBS represents LionHeart's first clinical experience, while HeartMate had been implanted in 1,000 patients as a bridge to transplant prior to REMATCH (1"The Gray Sheet" June 30, 2003, In Brief)...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.